Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors.

Sobarzo A, Stonier SW, Radinsky O, Gelkop S, Kuehne AI, Edri A, Herbert AS, Fedida-Metula S, Lutwama JJ, Yavelsky V, Davis C, Porgador A, Dye JM, Lobel L.

EBioMedicine. 2019 Aug;46:215-226. doi: 10.1016/j.ebiom.2019.07.021. Epub 2019 Jul 17.

2.

Protocadherin-1 is essential for cell entry by New World hantaviruses.

Jangra RK, Herbert AS, Li R, Jae LT, Kleinfelter LM, Slough MM, Barker SL, Guardado-Calvo P, Román-Sosa G, Dieterle ME, Kuehne AI, Muena NA, Wirchnianski AS, Nyakatura EK, Fels JM, Ng M, Mittler E, Pan J, Bharrhan S, Wec AZ, Lai JR, Sidhu SS, Tischler ND, Rey FA, Moffat J, Brummelkamp TR, Wang Z, Dye JM, Chandran K.

Nature. 2018 Nov;563(7732):559-563. doi: 10.1038/s41586-018-0702-1. Epub 2018 Nov 21.

3.

NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry.

Raaben M, Jae LT, Herbert AS, Kuehne AI, Stubbs SH, Chou YY, Blomen VA, Kirchhausen T, Dye JM, Brummelkamp TR, Whelan SP.

Cell Host Microbe. 2017 Nov 8;22(5):688-696.e5. doi: 10.1016/j.chom.2017.10.002.

4.

Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses.

Stonier SW, Herbert AS, Kuehne AI, Sobarzo A, Habibulin P, Dahan CVA, James RM, Egesa M, Cose S, Lutwama JJ, Lobel L, Dye JM.

J Exp Med. 2017 Sep 4;214(9):2563-2572. doi: 10.1084/jem.20170161. Epub 2017 Jul 19.

5.

Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.

Zhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang CI, Lei L, Fels JM, Vu H, Shulenin S, Turonis AN, Kuehne AI, Liu G, Ta M, Wang Y, Sundling C, Xiao Y, Spence JS, Doranz BJ, Holtsberg FW, Ward AB, Chandran K, Dye JM, Qiu X, Li Y, Aman MJ.

Cell. 2017 May 18;169(5):891-904.e15. doi: 10.1016/j.cell.2017.04.038.

6.

A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses.

Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE Jr, Aman MJ, Dye JM, Lai JR, Chandran K.

Science. 2016 Oct 21;354(6310):350-354. Epub 2016 Sep 8.

7.

Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses.

Natesan M, Jensen SM, Keasey SL, Kamata T, Kuehne AI, Stonier SW, Lutwama JJ, Lobel L, Dye JM, Ulrich RG.

Clin Vaccine Immunol. 2016 Aug 5;23(8):717-24. doi: 10.1128/CVI.00107-16. Print 2016 Aug.

8.

Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors.

Sobarzo A, Stonier SW, Herbert AS, Ochayon DE, Kuehne AI, Eskira Y, Fedida-Metula S, Tali N, Lewis EC, Egesa M, Cose S, Lutwama JJ, Yavelsky V, Dye JM, Lobel L.

Viruses. 2016 May 11;8(5). pii: E133. doi: 10.3390/v8050133.

9.

Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle.

Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA.

Sci Rep. 2016 Apr 25;6:24897. doi: 10.1038/srep24897.

10.

Monoclonal antibody therapy for Junin virus infection.

Zeitlin L, Geisbert JB, Deer DJ, Fenton KA, Bohorov O, Bohorova N, Goodman C, Kim D, Hiatt A, Pauly MH, Velasco J, Whaley KJ, Altmann F, Gruber C, Steinkellner H, Honko AN, Kuehne AI, Aman MJ, Sahandi S, Enterlein S, Zhan X, Enria D, Geisbert TW.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63. doi: 10.1073/pnas.1600996113. Epub 2016 Apr 4.

11.

Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats.

Ng M, Ndungo E, Kaczmarek ME, Herbert AS, Binger T, Kuehne AI, Jangra RK, Hawkins JA, Gifford RJ, Biswas R, Demogines A, James RM, Yu M, Brummelkamp TR, Drosten C, Wang LF, Kuhn JH, Müller MA, Dye JM, Sawyer SL, Chandran K.

Elife. 2015 Dec 23;4. pii: e11785. doi: 10.7554/eLife.11785.

12.

Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

Bounds CE, Kwilas SA, Kuehne AI, Brannan JM, Bakken RR, Dye JM, Hooper JW, Dupuy LC, Ellefsen B, Hannaman D, Wu H, Jiao JA, Sullivan EJ, Schmaljohn CS.

PLoS One. 2015 Sep 30;10(9):e0137786. doi: 10.1371/journal.pone.0137786. eCollection 2015.

13.

Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail.

Kugelman JR, Kugelman-Tonos J, Ladner JT, Pettit J, Keeton CM, Nagle ER, Garcia KY, Froude JW, Kuehne AI, Kuhn JH, Bavari S, Zeitlin L, Dye JM, Olinger GG, Sanchez-Lockhart M, Palacios GF.

Cell Rep. 2015 Sep 29;12(12):2111-20. doi: 10.1016/j.celrep.2015.08.038. Epub 2015 Sep 10.

14.

Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo.

Herbert AS, Davidson C, Kuehne AI, Bakken R, Braigen SZ, Gunn KE, Whelan SP, Brummelkamp TR, Twenhafel NA, Chandran K, Walkley SU, Dye JM.

MBio. 2015 May 26;6(3):e00565-15. doi: 10.1128/mBio.00565-15.

15.

Immune memory to Sudan virus: comparison between two separate disease outbreaks.

Sobarzo A, Eskira Y, Herbert AS, Kuehne AI, Stonier SW, Ochayon DE, Fedida-Metula S, Balinandi S, Kislev Y, Tali N, Lewis EC, Lutwama JJ, Dye JM, Yavelsky V, Lobel L.

Viruses. 2015 Jan 6;7(1):37-51. doi: 10.3390/v7010037.

16.

Virus entry. Lassa virus entry requires a trigger-induced receptor switch.

Jae LT, Raaben M, Herbert AS, Kuehne AI, Wirchnianski AS, Soh TK, Stubbs SH, Janssen H, Damme M, Saftig P, Whelan SP, Dye JM, Brummelkamp TR.

Science. 2014 Jun 27;344(6191):1506-10. doi: 10.1126/science.1252480.

17.

Persistent immune responses after Ebola virus infection.

Sobarzo A, Ochayon DE, Lutwama JJ, Balinandi S, Guttman O, Marks RS, Kuehne AI, Dye JM, Yavelsky V, Lewis EC, Lobel L.

N Engl J Med. 2013 Aug 1;369(5):492-3. doi: 10.1056/NEJMc1300266. No abstract available.

18.

Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).

Sobarzo A, Groseth A, Dolnik O, Becker S, Lutwama JJ, Perelman E, Yavelsky V, Muhammad M, Kuehne AI, Marks RS, Dye JM, Lobel L.

J Infect Dis. 2013 Jul 15;208(2):299-309. doi: 10.1093/infdis/jit162. Epub 2013 Apr 12.

PMID:
23585686
19.

Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.

Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM.

J Virol. 2013 May;87(9):4952-64. doi: 10.1128/JVI.03361-12. Epub 2013 Feb 13.

20.

Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease.

Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5034-9. doi: 10.1073/pnas.1200409109. Epub 2012 Mar 12.

21.

Ebola virus entry requires the host-programmed recognition of an intracellular receptor.

Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, Ruthel G, Pfeffer SR, Dye JM, Whelan SP, Brummelkamp TR, Chandran K.

EMBO J. 2012 Apr 18;31(8):1947-60. doi: 10.1038/emboj.2012.53. Epub 2012 Mar 6.

22.

Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus.

Olal D, Kuehne AI, Bale S, Halfmann P, Hashiguchi T, Fusco ML, Lee JE, King LB, Kawaoka Y, Dye JM Jr, Saphire EO.

J Virol. 2012 Mar;86(5):2809-16. doi: 10.1128/JVI.05549-11. Epub 2011 Dec 14.

23.

A shared structural solution for neutralizing ebolaviruses.

Dias JM, Kuehne AI, Abelson DM, Bale S, Wong AC, Halfmann P, Muhammad MA, Fusco ML, Zak SE, Kang E, Kawaoka Y, Chandran K, Dye JM, Saphire EO.

Nat Struct Mol Biol. 2011 Nov 20;18(12):1424-7. doi: 10.1038/nsmb.2150.

24.

Ebola virus entry requires the cholesterol transporter Niemann-Pick C1.

Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR.

Nature. 2011 Aug 24;477(7364):340-3. doi: 10.1038/nature10348.

25.

Safety and immunogenicity of a live-attenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques.

McKee KT Jr, Oro JG, Kuehne AI, Spisso JA, Mahlandt BG.

Am J Trop Med Hyg. 1993 Mar;48(3):403-11.

PMID:
8385886
26.

Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques.

McKee KT Jr, Oro JG, Kuehne AI, Spisso JA, Mahlandt BG.

Intervirology. 1992;34(3):154-63.

PMID:
1338783

Supplemental Content

Loading ...
Support Center